Cannell Capital LLC Has $7.27 Million Position in MiMedx Group, Inc. (NASDAQ:MDXG)
Cannell Capital LLC raised its stake in MiMedx Group, Inc. (NASDAQ:MDXG – Free Report) by 172.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,100,256 shares of the company’s stock after purchasing an additional 696,594 shares during the period. Cannell Capital LLC owned 0.95% of MiMedx Group worth $7,273,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently modified their holdings of MDXG. Swiss National Bank increased its holdings in shares of MiMedx Group by 8.2% in the first quarter. Swiss National Bank now owns 172,400 shares of the company’s stock valued at $812,000 after purchasing an additional 13,000 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of MiMedx Group by 16.7% in the first quarter. JPMorgan Chase & Co. now owns 78,218 shares of the company’s stock valued at $368,000 after purchasing an additional 11,208 shares during the last quarter. Acadian Asset Management LLC acquired a new position in shares of MiMedx Group in the first quarter valued at $151,000. MetLife Investment Management LLC increased its holdings in shares of MiMedx Group by 56.2% in the first quarter. MetLife Investment Management LLC now owns 62,811 shares of the company’s stock valued at $296,000 after purchasing an additional 22,593 shares during the last quarter. Finally, Rhumbline Advisers increased its holdings in shares of MiMedx Group by 5.5% in the first quarter. Rhumbline Advisers now owns 120,353 shares of the company’s stock valued at $567,000 after purchasing an additional 6,250 shares during the last quarter. 43.85% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
A number of equities research analysts have recently issued reports on the stock. StockNews.com assumed coverage on shares of MiMedx Group in a research report on Thursday, October 5th. They issued a “strong-buy” rating for the company. Mizuho reduced their target price on shares of MiMedx Group from $14.00 to $12.00 and set a “buy” rating for the company in a research report on Tuesday, October 31st. Finally, Craig Hallum assumed coverage on shares of MiMedx Group in a research report on Friday, October 27th. They issued a “buy” rating and a $12.00 target price for the company. Three equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, MiMedx Group currently has an average rating of “Buy” and a consensus target price of $11.67.
View Our Latest Report on MiMedx Group
MiMedx Group Price Performance
MDXG traded up $0.08 on Friday, hitting $8.01. 468,732 shares of the stock were exchanged, compared to its average volume of 601,850. MiMedx Group, Inc. has a 12 month low of $2.43 and a 12 month high of $8.60. The business has a 50-day moving average of $6.92 and a two-hundred day moving average of $6.97. The company has a debt-to-equity ratio of 36.82, a current ratio of 3.54 and a quick ratio of 3.10. The firm has a market capitalization of $932.18 million, a price-to-earnings ratio of -400.50 and a beta of 1.66.
MiMedx Group (NASDAQ:MDXG – Get Free Report) last posted its quarterly earnings data on Monday, October 30th. The company reported $0.05 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.01. The firm had revenue of $81.71 million for the quarter, compared to the consensus estimate of $76.69 million. Sell-side analysts forecast that MiMedx Group, Inc. will post 0.09 EPS for the current fiscal year.
Insider Buying and Selling
In other news, CFO Rice Doug acquired 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 21st. The stock was acquired at an average price of $7.16 per share, with a total value of $35,800.00. Following the completion of the transaction, the chief financial officer now directly owns 102,200 shares of the company’s stock, valued at approximately $731,752. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 19.90% of the stock is currently owned by company insiders.
MiMedx Group Profile (Free Report)
MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.
See Also
Want to see what other hedge funds are holding MDXG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MiMedx Group, Inc. (NASDAQ:MDXG – Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider MiMedx Group, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and MiMedx Group wasn’t on the list.
While MiMedx Group currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Click the link below and we’ll send you MarketBeat’s list of seven best retirement stocks and why they should be in your portfolio.